Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISLAND-SLE: Rezpegaldesleukin in SLE
NCT04433585Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Aug 2020
- Primary completion
- Jan 2023
- Modality
- Biologic, rProtein (Recombinant Protein), Polyethylene glycol conjugate
- Countries
- 19
01
Overview
A Phase 2 trial of rezpegaldesleukin in systemic lupus erythematosus (SLE), sponsored by Nektar Therapeutics. Started Aug 2020; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04433585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04433585.